Opinion
Read expert opinions and analysis on policy, markets, and culture in the cannabis industry.
Opinion · page 2
- Medical Cannabis
Who Really Benefits from Britain’s Medical Cannabis System?
Written for Business of Cannabis by Saxon Coop, Founder & CEO of Toke.
- Hemp Industry
Is the US Hemp Ban Punishing the Wrong People?
This article was written for Business of Cannabis by Scott Mazza, Co-Founder of Vitality CBD and Certified Headies Uncertainty isn’t what hemp needs right now.
- Investment & Finance
Cannabis at an Inflexion Point: A Structural Repricing Ahead
Having spent over 30 years in advisory roles in financial markets prior to entering the cannabinoid industry, I lived through many hyperbolic boom/bust market cycles.
- Opinion
Europe’s Medical Cannabis Market Has Grown Up, Now Its Supply Chain Needs To
Written by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma.
- Investment & Finance
Cannabis at an Inflexion Point: Why Capital Is Missing the Opportunity
For much of the past five years, the cannabis industry has been defined by disappointment.
- Opinion
From Green Success to BH Labs: Why the Next Cannabis Leaders Will Look More Like Technology Companies
As Europe’s medical cannabis market matures, a new category of operator is beginning to emerge.
- Industry Trends
DEA’s Schedule III Cannabis Order: A Free-For-All for Telehealth Platforms, or the Perfect Setup for the Entire Industry?
As the industry’s (more than justified) excitement over last week’s rescheduling announcement begins to subside, the regulatory reality is settling in.
- Opinion
Is the ‘Commercial Scale’ of Medical Cannabis in the UK Inappropriate?
As the UK’s medical cannabis industry continues to come under fierce scrutiny from the country’s mainstream media, James Duckenfield, CEO of UK-based cannabis cultivator Glass Pharms, argues that the focus should be on ensuring compliance with the existing regulatory framework rather than sensationalising a prescribing rate that remains a small fraction of demonstrable clinical need.
- Industry Trends
Is a Cannabis M&A Tidal Wave on the Way?
At the end of the month (March 30, 2026), shareholders of one of the fastest growing Canadian licenced producers, Organigram Global, will convene to decide the fate of its proposed €250m acquisition of Sanity Group.
- Clinical Research
Rescheduling Will Reprice Medical IP, Not Retail Footprints
US cannabis rescheduling is unlikely to trigger a land grab.
- Industry Trends
Organigram Acquires Sanity Group: When Big Tobacco Moves into Cannabis
By Dr Sebastian Marincolo, Director of Strategic Content & Editorial, Weed.de Canadian cannabis company Organigram Global has agreed to acquire Berlin’s Sanity Group for up to 227 million euros, financed in large part by a roughly 65 million Canadian dollar capital injection from its largest shareholder, British American Tobacco (BAT).
- Industry Trends
US Cannabis Rescheduling: A Victory or a Federal Trap?
US cannabis rescheduling, much like President Donald Trump who is rightly credited for finally pushing it forward, has sucked all the oxygen out of the room for the last two years.
